Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial

Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study

(2018) Ton Fang et al.   LANCET NEUROLOGY

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model

(2018) Henk-Jan Westeneng et al.   LANCET NEUROLOGY

Human Endogenous Retroviruses in Neurological Diseases

(2018) Patrick Küry et al.   TRENDS IN MOLECULAR MEDICINE

Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins

(2018) Jens Mayer et al.   Molecular Neurodegeneration

Human endogenous retrovirus-K (HML-2): a comprehensive review

(2018) Marta Garcia-Montojo et al.   CRITICAL REVIEWS IN MICROBIOLOGY

Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors

(2017) Rafael Contreras-Galindo et al.   JOURNAL OF VIROLOGY

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

(2017) Vincent Meininger et al.   LANCET NEUROLOGY

Urinary p75 ECD

(2017) Stephanie R. Shepheard et al.   NEUROLOGY

Inhibition of human endogenous retrovirus-K by antiretroviral drugs

(2017) Richa Tyagi et al.   Retrovirology

Amyotrophic lateral sclerosis: moving towards a new classification system

(2016) Ammar Al-Chalabi et al.   LANCET NEUROLOGY

Fitting Linear Mixed-Effects Models Usinglme4

(2015) Douglas Bates et al.   Journal of Statistical Software

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis

(2015) C.-H. Lu et al.   NEUROLOGY

A revision of the El Escorial criteria - 2015

(2015) Albert Ludolph et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial

(2015) Susanna B. Park et al.   EBioMedicine

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects

(2014) S. L. Letendre et al.   CLINICAL INFECTIOUS DISEASES

Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study

(2014) Ching-Hua Lu et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Genomic Flexibility of Human Endogenous Retrovirus Type K

(2014) D. Dube et al.   JOURNAL OF VIROLOGY

Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale

(2014) Rubika Balendra et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Retroviruses and amyotrophic lateral sclerosis

(2013) Tariq Alfahad et al.   ANTIVIRAL RESEARCH

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

(2013) Merit E Cudkowicz et al.   LANCET NEUROLOGY

The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

(2011) Kelly Posner et al.   AMERICAN JOURNAL OF PSYCHIATRY

Amyotrophic lateral sclerosis

(2011) Matthew C Kiernan et al.   LANCET

Clinical diagnosis and management of amyotrophic lateral sclerosis

(2011) Orla Hardiman et al.   Nature Reviews Neurology

A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis

(2010) Mamede de Carvalho et al.   Amyotrophic Lateral Sclerosis

Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis

(2010) Renée Douville et al.   ANNALS OF NEUROLOGY

Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate

(2008) A. L. McCormick et al.   NEUROLOGY